These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment. Dabelić N; Jukić T; Fröbe A Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884 [TBL] [Abstract][Full Text] [Related]
9. Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays? Niederle MB; Scheuba C; Riss P; Selberherr A; Koperek O; Niederle B Thyroid; 2020 Jul; 30(7):974-984. PubMed ID: 32056502 [No Abstract] [Full Text] [Related]
10. Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: prognostic implications. Cavalheiro BG; Junqueira CR; Brandão LG Thyroid; 2008 Aug; 18(8):865-71. PubMed ID: 18651826 [TBL] [Abstract][Full Text] [Related]
11. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. Del Rivero J; Donahue RN; Marté JL; Gramza AW; Bilusic M; Rauckhorst M; Cordes L; Merino MJ; Dahut WL; Schlom J; Gulley JL; Madan RA Front Endocrinol (Lausanne); 2020; 11():490. PubMed ID: 32849281 [TBL] [Abstract][Full Text] [Related]
12. Fine-needle aspiration cytology for medullary thyroid carcinoma: a single institutional experience in Japan. Suzuki A; Hirokawa M; Takada N; Higuchi M; Ito A; Yamao N; Hayashi T; Kuma S; Miyauchi A Endocr J; 2017 Nov; 64(11):1099-1104. PubMed ID: 28883261 [TBL] [Abstract][Full Text] [Related]
13. Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker. Zhan S; Li J; Wang T; Ge W Oncologist; 2018 Dec; 23(12):1415-1425. PubMed ID: 29739896 [TBL] [Abstract][Full Text] [Related]
14. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center. Kim SJ; Yun HJ; Shin SJ; Lee YS; Chang HS Front Endocrinol (Lausanne); 2021; 12():747704. PubMed ID: 34803914 [TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin. Zhou Q; Yue S; Cheng Y; Jin J; Xu H Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629 [TBL] [Abstract][Full Text] [Related]
17. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695 [TBL] [Abstract][Full Text] [Related]
19. Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies. Yeh T; Yeung M; Sherman EJ; Tuttle RM; Sabra MM Thyroid; 2020 Aug; 30(8):1112-1119. PubMed ID: 32131709 [No Abstract] [Full Text] [Related]
20. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations. Barletta JA; Nosé V; Sadow PM Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]